Creso Pharma Ltd
ASX:CPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (14.7), the stock would be worth AU$-0.12 (1 634% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1 | AU$0.01 |
0%
|
| Industry Average | 14.7 | AU$-0.12 |
-1 634%
|
| Country Average | 21 | AU$-0.18 |
-2 294%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Creso Pharma Ltd
ASX:CPH
|
17.7m AUD | -1 | -0.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 144 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 29.2 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 35.3 | 27.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 19.2 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 24.6 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 43.8 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 21.9 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 11.7 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.2 |
| Median | 21 |
| 70th Percentile | 32.6 |
| Max | 583 153.2 |
Other Multiples
Creso Pharma Ltd
Glance View
Creso Pharma Ltd. develops, registers and commercializes pharmaceutical-grade cannabis and hemp-hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health. The firm is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. The Company, through its subsidiary is also engaged in cultivates and harvests cannabis plants and supplies dried cannabis plant retail products. The firm is operating medical facility in Windsor, Nova Scotia with 6 treatment rooms and a laboratory dedicated to performing psychedelic-assisted psychotherapy and clinical research.
